Physician profile
Elizabeth Ferluga
NPI 1114121605
$76,958.71
in general payments reported to CMS, 2019-2025
46 companies · $4,630 in 2025
The $4,630 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,790 · 2020: $1,643 · 2021: $11K · 2022: $13K · 2023: $32K · 2024: $12K · 2025: $4,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,525 · Travel and Lodging: $4,426 · Honoraria: $3,740 · Food and Beverage: $2,387 · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,190.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,525.00 |
| Travel and Lodging | $4,425.96 |
| Honoraria | $3,740.00 |
| Food and Beverage | $2,387.36 |
| Education | $445.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $44,480.38 | 2020-2024 | Ingrezza, Ongentys |
| Abbvie INC. | $10,162.52 | 2019-2024 | |
| Allergan, INC. | $8,264.18 | 2019-2022 | |
| Mdd US Operations, LLC | $5,964.39 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,729.29 | 2019-2023 | Austedo, Ajovy |
| Biohaven Pharmaceuticals, INC. | $1,157.29 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $679.19 | 2019-2023 | Nuplazid |
| Amneal Pharmaceuticals LLC | $488.88 | 2020-2024 | Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $465.16 | 2022 | |
| Supernus Pharmaceuticals, INC. | $324.03 | 2019-2023 | |
| Amgen INC. | $322.78 | 2019-2020 | |
| Lilly USA, LLC | $300.95 | 2019-2023 | Emgality, Reyvow |
| Kyowa Kirin, INC. | $234.60 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $221.88 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $204.11 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Ferluga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.